Medical News

RSS

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

To honor six cancer survivors featured in its newest international ad campaign, NanoString Technologies, Inc. will donate $6,000 to the American Cancer Society. The “Dear Cancer Researcher” participants courageously shared their personal stories of triumph to help the biotechnology company launch its newest product, nCounter SPRINT™ Profiler, a system that gives researchers the tools and opportunity to think beyond current everyday practice.

From NanoString Technologies 9 Oct 2015

Avita Medical gains two CE marks to complete skin healing portfolio

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.

9 Oct 2015

Research on investigational menopause drug wins first prize

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at the 26th annual North American Menopause Society (NAMS) meeting in Las Vegas last week.

9 Oct 2015

CRF Health launches new website and industry-first eCOA resource hub

CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today launched its new website, www.crfhealth.com, which includes an industry-first online eCOA resource hub. The multimedia platform provides a wide range of webinars, eBooks, articles and videos covering the effective implementation, management and scaling of eCOA technology for global clinical trials.

9 Oct 2015

Minor hallucinations may predate Parkinson motor symptoms

About four in 10 patients with untreated Parkinson’s disease experience minor hallucinations, research shows.

8 Oct 2015

Daclizumab HYP superior to interferon in relapsing–remitting MS

The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.

8 Oct 2015

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

JKTG Foundation announces over $160K in awards to support next generation of health policy research

Today, the Jayne Koskinas Ted Giovanis Foundation announced over $160K in awards to support the next generation of health policy research and promote better healthcare for patients. Four graduate researchers in the field of health policy and administration at Brown University, Georgetown University, Harvard University and The Johns Hopkins University received Dissertation Support Grants (DSGs) to aid their research.

8 Oct 2015

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, recently launched a company-wide diabetes awareness campaign that will run through November.

8 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso (sufentanil sublingual tablet system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting.

8 Oct 2015

Study assesses customer satisfaction with blood glucose meters

Training materials that are accessible and easy to understand contribute to an overall increase in satisfaction among adults or parents of children with Type 1 or Type 2 diabetes who use a blood glucose meter, and satisfaction is significantly higher when they understand how to use their meter, according to the J.D. Power 2015 U.S. Blood Glucose Meter Satisfaction Study.

8 Oct 2015

Research: Many Americans use prescription pain relievers, most people see abuse as serious health issue

More than one in four Americans has taken prescription painkillers in the past year, even as a majority say that abuse of these medications is a very serious public health concern, according to new Johns Hopkins Bloomberg School of Public Health research.

8 Oct 2015

Lund researchers one step closer to developing implantable electrodes for capturing brain function

For nearly nine years, researchers at Lund University have been working on developing implantable electrodes that can capture signals from single neurons in the brain over a long period of time - without causing brain tissue damage. They are now one big step closer to reaching this goal, and the results are published in the scientific journal Frontiers in Neuroscience.

8 Oct 2015

Medical News

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

Avita Medical gains two CE marks to complete skin healing portfolio

Research on investigational menopause drug wins first prize

CRF Health launches new website and industry-first eCOA resource hub

Minor hallucinations may predate Parkinson motor symptoms

Daclizumab HYP superior to interferon in relapsing–remitting MS

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

JKTG Foundation announces over $160K in awards to support next generation of health policy research

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Up to 1 billion people could be at risk of going blind by 2050, say researchers

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

Study assesses customer satisfaction with blood glucose meters

Research: Many Americans use prescription pain relievers, most people see abuse as serious health issue

Lund researchers one step closer to developing implantable electrodes for capturing brain function

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News